NCT06555640View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

October 30, 2025

Conditions
Severe Hypertriglyceridemia
Interventions
DRUG

DR10624 Injection

Drug: DR10624 injection

DRUG

Placebo

Drug: placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY